Modulation of the antidepressant and antisuicidal efficacy of low-dose ketamine infusion via the mTORC1 modulator, Rapamycin: A double-blind, randomized, placebo controlled trial combined with the neuropsychological and functional connectivity MRI study.
Not Applicable
Recruiting
- Conditions
- treatment-resistant depression
- Registration Number
- JPRN-UMIN000049877
- Lead Sponsor
- Ministry of Science and Technology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Major medical conditions (e.g., head injury, epilepsy, severe renal diseases and cancer). (2) Other axis I psychiatric disorders such as schizophrenia, delusional disorder, organic brain syndrome, and dementia. (3) Pregnancy. (4) Substance abuse in previous 6 months such as cocaine, marijuana, opium, ketamine, PCP (phencyclidine). (5) Current use of NMDA receptor antagonist (Amantadine, Rimantadine, Lamotrigine, Memantine, Dextromethorphan). (6) Alcohol abuse / dependence within 6 months. (7) Attempt suicide in hospital. (8) Allergy to ketamine or rapamycin.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method